This critical step, according to the ADA website in the development of an artificial pancreas is an important milestone for people with type 1 diabetes.
The MiniMed 670G is the first pump-sensor system to automatically adjust basal insulin levels, up or down, based on continuous glucose readings from an integrated continuous glucose monitor.
Patients will continue to make insulin dosing decisions at mealtime, with the MiniMed 670G providing dose recommendations based on the patient’s blood glucose levels and trends.
Patients will also need to perform finger-stick glucose checks for calibration of the device.
The system is appropriate for anyone who is currently using or is a good candidate for an insulin pump.
The FDA has approved the MiniMed 670G for people age 14 and older.
We are excited for this advancement, and we look forward to the development of the next phase of automated systems that can provide doses of . We envision that these incremental innovations will lead to a fully automated closed-loop system to provide optimal control and independence for people with diabetes.
HOW DOES A CONTINUOS GLUCOSE MONITOR (CGM) WORK
CGM is a way to measure glucose levels in real-time throughout the day and night.
A tiny electrode called a glucose sensor is inserted under the skin to measure glucose levels in tissue fluid.
It is connected to a transmitter that sends the information via wireless radio frequency to a monitoring and display device. The device can detect and notify you if your glucose is reaching a high or low limit.
To engage with the Diabetes Online Community follow The Nigeria Diabetes Online Community on Facebook NGDOC and on Twitter @theNGdoc
– See more at: http://www.diabetes.org/newsroom/press-releases/2016/american-diabetes-association-FDA-approval-first-hybrid.html?referrer=https://t.co/VkIIhiSJFd#sthash.qkMPxHBk.dpuf